• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    6/10/22 5:48:39 PM ET
    $ABVC
    $ACXP
    $ALRN
    $BLUE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVC alert in real time by email

    Gainers

    • bluebird bio (NASDAQ:BLUE) shares rose 53.4% to $6.12 during Friday's after-market session. Trading volume for this security closed at 5.0 million, accounting for 206.3% of its average full-day volume over the last 100 days. The company's market cap stands at $437.2 million.
    • Aileron Therapeutics (NASDAQ:ALRN) stock moved upwards by 27.46% to $0.53. The company's market cap stands at $48.1 million.
    • ABVC BioPharma (NASDAQ:ABVC) shares moved upwards by 20.0% to $1.08. The company's market cap stands at $34.8 million.
    • Lixte Biotech Hldgs (NASDAQ:LIXT) shares increased by 10.22% to $0.83. The market value of their outstanding shares is at $13.8 million.
    • Minerva Neurosciences (NASDAQ:NERV) stock rose 8.2% to $0.43. The company's market cap stands at $18.3 million.
    • Oncternal Therapeutics (NASDAQ:ONCT) shares moved upwards by 7.31% to $1.32. The company's market cap stands at $65.2 million.

    Losers

    • Alpha Tau Medical (NASDAQ:DRTS) stock decreased by 15.1% to $8.2 during Friday's after-market session. The company's market cap stands at $561.5 million.
    • Elevation Oncology (NASDAQ:ELEV) stock decreased by 11.96% to $1.62. The market value of their outstanding shares is at $37.6 million.
    • Acurx Pharmaceuticals (NASDAQ:ACXP) shares fell 7.43% to $3.49. The market value of their outstanding shares is at $35.8 million.
    • Stealth BioTherapeutics (NASDAQ:MITO) shares fell 7.15% to $0.26. The market value of their outstanding shares is at $19.1 million.
    • ViewRay (NASDAQ:VRAY) shares declined by 6.82% to $2.6. The company's market cap stands at $469.1 million.
    • Zosano Pharma (NASDAQ:ZSAN) shares fell 6.75% to $0.52. The market value of their outstanding shares is at $2.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $ACXP
    $ALRN
    $BLUE

    CompanyDatePrice TargetRatingAnalyst
    Alpha Tau Medical Ltd.
    $DRTS
    3/4/2026$5.00Overweight → Neutral
    Piper Sandler
    Elevation Oncology Inc.
    $ELEV
    3/24/2025$5.00 → $1.00Overweight → Equal-Weight
    Stephens
    Elevation Oncology Inc.
    $ELEV
    3/21/2025$1.00Outperform → Market Perform
    Leerink Partners
    Elevation Oncology Inc.
    $ELEV
    3/21/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Elevation Oncology Inc.
    $ELEV
    3/21/2025$0.70Overweight → Neutral
    Piper Sandler
    bluebird bio Inc.
    $BLUE
    2/24/2025Underweight → Neutral
    Analyst
    bluebird bio Inc.
    $BLUE
    2/24/2025$29.00Overweight
    Analyst
    Elevation Oncology Inc.
    $ELEV
    1/3/2025Outperform
    William Blair
    More analyst ratings

    $ABVC
    $ACXP
    $ALRN
    $BLUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alpha Tau downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Alpha Tau from Overweight to Neutral and set a new price target of $5.00

    3/4/26 8:30:52 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Elevation Oncology downgraded by Stephens with a new price target

    Stephens downgraded Elevation Oncology from Overweight to Equal-Weight and set a new price target of $1.00 from $5.00 previously

    3/24/25 8:34:27 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Elevation Oncology from Outperform to Market Perform and set a new price target of $1.00

    3/21/25 8:03:34 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVC
    $ACXP
    $ALRN
    $BLUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Avruch Michael

    3 - Alpha Tau Medical Ltd. (0001871321) (Issuer)

    3/18/26 7:04:47 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Kidron Nadav

    3 - Alpha Tau Medical Ltd. (0001871321) (Issuer)

    3/18/26 7:04:07 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Sofer Uzi

    3 - Alpha Tau Medical Ltd. (0001871321) (Issuer)

    3/18/26 7:03:38 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $ABVC
    $ACXP
    $ALRN
    $BLUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

    Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the second half of 2027 BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the presentation of clinical data from its open‑label safety trial evaluating roluperidone co‑administered with olanzapine at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress, held March 25

    3/25/26 4:05:00 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

    JERUSALEM, March 16, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference taking place on March 18-19, 2026. Event:Sidoti Virtual Small Cap ConferenceFormat:Company PresentationDate:March 18, 2026Time:10:00 – 10:30AM ETLocation:Virtual Mr. Levy will be available for 1x1 investor meetings at the conference. Please reach out to your Sidoti representative to schedule. About Alpha Tau Medical Ltd.  Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, de

    3/16/26 10:02:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

    STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the full year and fourth quarter ended December 31, 2025. Highlights of the fourth quarter ended December 31, 2025, or in some cases shortly thereafter, include:In October 2025, the Company received gross proceeds from the exercise of 170,068 Series F Warrants of approximately $1.4 million.Also in October 2025, we were one of five companies to make a formal presentation at IDWeek in Atlanta

    3/13/26 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ACXP
    $ALRN
    $BLUE
    SEC Filings

    View All

    SEC Form POS AM filed by ABVC BioPharma Inc.

    POS AM - ABVC BIOPHARMA, INC. (0001173313) (Filer)

    3/27/26 4:30:55 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ABVC BioPharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)

    3/27/26 4:05:35 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

    3/20/26 4:05:18 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ACXP
    $ALRN
    $BLUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Scodari Joseph C bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 800% to 27,708 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:32:30 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sailer Carl bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 22% to 137,183 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:31:59 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Luci David P bought $50,000 worth of shares (49,261 units at $1.01), increasing direct ownership by 5% to 1,097,458 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:31:33 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ACXP
    $ALRN
    $BLUE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

    For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

    8/17/22 2:12:27 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVC
    $ACXP
    $ALRN
    $BLUE
    Leadership Updates

    Live Leadership Updates

    View All

    LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

    BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company's Liora Technologies Europe Ltd. subsidiary ("Liora"). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE's acquisition of Liora's assets in November 2025 from Orbit Capital, Inc. Over his

    2/18/26 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

    BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successfully raising up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone for the treatment of negative symptoms in patients with schizophrenia, resubmission of it

    11/19/25 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

    -- Company Relocates Corporate Headquarters to Boca Raton -- Boca Raton, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced that Lourdes Felix and Guy Primus have joined the Company's Board of Directors, and Peter Stazzone has been named Chief Financial Officer. The Company also announced that it has relocated its corporate headquarters to Boca Raton. The new board members succeed Bas van der Baan, who remains Chief Scientific Officer of LIXTE, and René Bernards, PhD, who has been n

    9/3/25 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ACXP
    $ALRN
    $BLUE
    Financials

    Live finance-specific insights

    View All

    Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

    STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the full year and fourth quarter ended December 31, 2025. Highlights of the fourth quarter ended December 31, 2025, or in some cases shortly thereafter, include:In October 2025, the Company received gross proceeds from the exercise of 170,068 Series F Warrants of approximately $1.4 million.Also in October 2025, we were one of five companies to make a formal presentation at IDWeek in Atlanta

    3/13/26 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update

    STATEN ISLAND, N.Y., Feb. 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its full year and fourth quarter 2025 financial results on Friday, March 13, 2026 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:Date:                           Friday, March 13, 2026  Time:                     

    2/16/26 8:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

    Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT) a biotech company focused on advancing cancer treatments, today announced it has completed the acquisition of Liora Technologies Europe Ltd., a UK-based company pioneering electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora will become a wholly owned subsidiary of LIXTE. The acquisition includes Liora's proprietary flagship technology LiGHT Sys

    11/25/25 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ACXP
    $ALRN
    $BLUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 7:50:19 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by ABVC BioPharma Inc.

    SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)

    11/14/24 7:33:18 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 7:05:59 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care